Category: Press Releases

Posted on

KFSH&RC Strives to Pioneer in Maximizing Healthcare Spending Value

Dr. Al Fayyadh at Harvard: We Leverage Technology to Tackle Global Health Challenges

KFSH&RC Strives to Pioneer in Maximizing Healthcare Spending Value

Dr. Al Fayyadh at Harvard: We Leverage Technology to Tackle Global Health Challenges

RIYADH, Saudi Arabia, May 11, 2024 (GLOBE NEWSWIRE) — Dr. Majid Al Fayyadh, CEO of King Faisal Specialist Hospital and Research Centre (KFSH&RC) joined the Gulf Creatives Conference (GCC) at Harvard 2024. The event, GCC at Harvard, is organized by The Diwan, an organization run by graduate students at Harvard University. In his address, Dr. Al Fayyadh showcased the KFSH&RC’s journey since its inception in Riyadh almost five decades ago, highlighting how it has significantly reduced the need for patients to travel abroad for medical care. KFSH&RC has evolved into a premier provider of tertiary healthcare services and today offers cutting-edge treatments for heart diseases, tumors, organ transplantation, and genetic disorders.

Dr. Al Fayyadh discussed KFSH&RC’s transformation into an independent, non-profit foundation. This move, he indicated, aligns with the organization’s strategic vision to become a global healthcare innovation leader, emphasizing excellence, innovation, and investment in cutting-edge technology to tackle global health challenges.

KFSH&RC Strives to Pioneer in Maximizing Healthcare Spending Value

Dr. Al Fayyadh at Harvard: We Leverage Technology to Tackle Global Health Challenges

“The Saudi Leadership has outlined a clear vision for KFSH&RC, mandated by a royal decree transitioning the hospital into an independent Sui Generis, non-profit foundation,” stated His Excellency, Dr. Al Fayyadh.

He further highlighted that this transformation seeks to elevate global healthcare standards through increased independence and flexibility. This shift will allow KSFH&RC to optimize existing services, pursue new opportunities, and direct resources toward initiatives that promote human health and well-being both within the Kingdom and internationally. Ultimately, this move reinforces KFSH&RC’s dedication to patient-centered excellence.

Dr. Al Fayyadh pointed out that KFSH&RC envisions itself as a leader in maximizing the value of healthcare spending, adhering to evidence-based practices to ensure optimal patient outcomes. It seeks to remain at the forefront of global healthcare innovation, with initiatives designed to increase health equity and access worldwide. To achieve this, KFSH&RC will continue to invest in cutting-edge medical facilities, advanced diagnostic equipment, and state-of-the-art treatment technologies. Building on existing progress in areas like CAR T-cell therapy, robotic surgeries, organ transplants, and personalized medicine, the institution aims to achieve global competitiveness. This will be further supported by fostering an exceptional workforce, pursuing Nobel Prize-caliber breakthroughs, and strengthening strategic international collaborations.

KFSH&RC CEO at GCC Harvard 2

Dr. Al Fayyadh joined a panel discussion focusing on the evolving landscape of the healthcare sector and the positive outcomes of KFSH&RC’s ongoing transformation in patient care. He also addressed current challenges and anticipated future developments within the healthcare sector, emphasizing the profound impact of the hospital’s innovations on global healthcare advancement. Additionally, Dr. Al Fayyadh highlighted the effective role of the hospital’s transformative initiatives in aligning with the objectives of the Health Sector Transformation Program and Saudi Vision 2030.

KFSH&RC is recognized as one of the leading global institutions that provide specialized healthcare, drive innovation, and serve as an advanced medical research and education hub. It is dedicated to developing medical technologies and elevating healthcare standards worldwide, forging partnerships with leading local, regional, and international institutions to deliver world-class services in clinical, research, and educational domains.

For the second year running, KFSH&RC has retained its status as the leading institution in the Kingdom and ranks 20th globally among the top 250 academic medical centers worldwide. It is also recognized as the most valuable healthcare brand in the Kingdom and the Middle East in 2024, according to Brand Finance, and has been ranked among the world’s top 250 hospitals by Newsweek Magazine.

KFSH&RC CEO at GCC Harvard 1

About King Faisal Specialist Hospital and Research Centre:

King Faisal Specialist Hospital & Research Centre stands among the global leaders in providing specialized healthcare, driving innovation, and serving as an advanced medical research and education hub. Through strategic partnerships with prominent local, regional, and international institutions, the hospital is dedicated to advancing medical technologies and elevating healthcare standards worldwide.

The hospital has secured its position as the leading brand in the healthcare sector across the Kingdom and the Middle East, marking its second consecutive year as the most valuable healthcare brand. It ranks 9th within the Kingdom and 28th in the Middle East. The hospital distinguishes itself as the sole hospital globally to break into the top 10 brands in its country, as highlighted in two reports by “Brand Finance” on the 50 most valuable brands in Saudi Arabia and the 150 most valuable brands in the Middle East in 2024.

Due to the transformation programs and the Kingdom’s Vision 2030, launched by His Royal Highness the Crown Prince and Prime Minister – may God protect him – to enhance the Kingdom’s leadership in the global healthcare sector, KFSH&RC has emerged as a leading Academic Medical Centre in the Middle East and Africa. It maintained its 20th rank globally for the second consecutive year in 2024, according to “Brand Finance.” Additionally, it has been ranked among the top 250 hospitals globally in 2024 by the American magazine “Newsweek.”

For further information, please contact:

Mr. Essam AlZahrani, Acting Head of Media Affairs, 0555254429

Mr. Abdullah Alown, Media Coordination Officer, 0556294232

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/d9d0ed27-fa87-49ac-b72b-ccf5b5843637
https://www.globenewswire.com/NewsRoom/AttachmentNg/682fadee-20a5-4328-bf00-e036bc3350fd

GlobeNewswire Distribution ID 9115814

Posted on

Le King Faisal Specialist Hospital & Research Centre chef de file de la transformation du secteur de la santé en Arabie saoudite

RIYAD, Arabie saoudite, 10 mai 2024 (GLOBE NEWSWIRE) — Université de Harvard — Huit ans après le lancement du projet « Vision 2030 », l’Arabie saoudite a réalisé des pas de géant en termes d’innovation numérique et d’amélioration de l’accès à des soins de qualité. Des investissements stratégiques dans l’infrastructure hospitalière du pays, le recours à la technologie et l’embauche de personnel de talent ont conduit à des avancées révolutionnant les soins aux patients, tout en relevant les normes applicables aux soins de santé à l’échelle nationale. Ces efforts ont permis d’augmenter sensiblement l’espérance de vie moyenne, de réduire la mortalité et d’améliorer le bien-être général sur l’ensemble du royaume.

Le King Faisal Specialist Hospital & Research Centre, ci-après « KFSH&RC », soit l’hôpital spécialisé et centre de recherche King Faisal, se trouve au cœur de toutes ces réalisations. L’établissement doit son excellente réputation à ses soins et traitements thérapeutiques spécialisés dans des disciplines médicales majeures, à savoir l’oncologie, la cardiologie, la transplantation d’organes et la génétique. Il s’est imposé comme le leader des soins médicaux spécialisés, et contribue nettement à la construction d’un lendemain plus radieux et plus sain pour le royaume. À l’appui de son engagement envers des initiatives de santé reposant sur l’innovation numérique, des programmes éducatifs complets et des projets de recherche novateurs, il remodèle l’écosystème sanitaire local et en établit les nouvelles normes d’efficacité et d’accessibilité aux soins.

À l’heure où le monde avance au gré des avancées technologiques, et sous l’essor de la numérisation dans le royaume, le KFSH&RC se place à l’avant-garde de l’intégration de la santé numérique par rapport à ses homologues locaux. Pour ce faire, il s’appuie sur des pratiques de télémédecine de pointe, des consultations virtuelles et des outils alimentés par l’IA tels que le moteur d’IA ANFAL qui transforme la vie des patients au moyen d’informations prédictives et de soins personnalisés visant à leur apporter une satisfaction optimale.

Les initiatives de santé reposant sur l’innovation numérique à la main du KFSH&RC s’étendent à la lutte contre les menaces sanitaires d’envergure supérieure grâce à des technologies comme le séquençage du génome entier, ou SGE, ou la radiothérapie avancée. L’hôpital s’est également distingué à l’avant-garde de la transplantation d’organes en réalisant la toute première greffe de foie entièrement robotisée du monde. Il a par ailleurs introduit dans la région des innovations comme la valve pulmonaire transcathéter (VPT) Harmony pour améliorer la récupération et l’expérience des patients. Ces technologies induisent des protocoles de traitement personnalisés et améliorent tant la précision que la rapidité des diagnostics, tout en contribuant de manière significative au relèvement des normes de soins et à l’établissement d’une infrastructure sanitaire résiliente et durable, inscrite dans la conformité aux objectifs visés par le programme saoudien de transformation du secteur de la santé.

Le KFSH&RC continue de repousser les limites de la recherche médicale en s’attachant à relever les enjeux sanitaires sous tension et en contribuant à l’écosystème de la santé publique en Arabie saoudite par des découvertes telles que le gène PfAP2-MRP et son rôle critique dans le traitement du paludisme, ou l’identification de la nouvelle souche bactérienne Riyadhensis. Si ces découvertes ont amélioré la précision du diagnostic, elles ont également encouragé les interventions précoces, garantissant de fait un accompagnement efficace et pertinent aux patients, conformément aux objectifs nationaux ciblés sur la réduction de la prévalence des maladies chroniques.

Tous ces efforts sont étayés par les robustes projets éducatifs du KFSH&RC, qui formattent la prochaine génération de professionnels de la santé au moyen de programmes de formation et d’opportunités de coopération internationale.

Brand Finance a distingué le capital de marque de l’hôpital en tête des établissements d’Arabie saoudite et du Moyen-Orient à deux reprises, le plaçant respectivement à la 9e et 28e position régionale. De plus, le KFSH&RC se distingue comme le seul hôpital du monde à se hisser au rang des dix marques les plus valorisées du pays.

À propos du King Faisal Specialist Hospital & Research Centre (KFSH&RC) :

Le King Faisal Specialist Hospital & Research Centre (KFSH&RC) est un établissement de soins de santé de premier plan au Moyen-Orient, conçu pour être le choix idéal de tout patient en quête de soins de santé spécialisés. L’hôpital s’enorgueillit d’une riche histoire dans le traitement des cancers, des maladies cardiovasculaires, des transplantations d’organes, des neurosciences et de la génétique.

En 2024, « Brand Finance » l’a classé en tête des centres médicaux universitaires de la région MENA, et parmi les 20 premiers au niveau mondial pour la deuxième année de suite. En outre, en 2024, le magazine Newsweek l’a reconnu comme l’un des principaux fournisseurs de soins de santé dans le monde.

Dans le cadre du projet « Saudi Vision 2030 », un décret royal a été publié le 21 décembre 2021, visant la transformation de l’hôpital en une structure indépendante à but non lucratif sous la tutelle du gouvernement. Cette initiative a ouvert la voie à un programme de transformation complet visant à atteindre un leadership mondial dans le domaine des soins de santé grâce à l’excellence et à l’innovation.

COORDONNÉES

Pour plus d’informations, veuillez contacter :

M. Essam Al-Zahrani, Chef des affaires médiatiques, 0555254429

M. Abdullah Al-Awn, Coordinateur médias, 0556294232

Une photo accompagnant ce communiqué est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/003e76ab-3d93-42d4-9edf-5e652a14c559

GlobeNewswire Distribution ID 9115602

Posted on

King Faisal Specialist Hospital & Research Centre Lidera Transformação do Setor de Saúde na Arábia Saudita

RIADE, Arábia Saudita, May 10, 2024 (GLOBE NEWSWIRE) — Harvard University — Com oito anos do Vision 2030, a Arábia Saudita fez avanços significativos com inovações digitais e acesso aprimorado aos cuidados de qualidade. Investimentos estratégicos em infraestrutura, tecnologia e talento resultaram em avanços que revolucionaram a prestação de cuidados ao paciente e elevaram os padrões de cuidados de saúde localmente. Esses esforços aumentaram notavelmente a expectativa média de vida, reduziram as taxas de mortalidade e melhoraram o bem-estar geral em todo o Reino.

Essencial para essas conquistas, o King Faisal Specialist Hospital & Research Centre (KFSH&RC), conhecido por seus cuidados e tratamentos especializados em áreas críticas como oncologia, cardiologia, transplante de órgãos e genética, se posicionou como líder em atendimento especializado ao paciente, assumindo a responsabilidade de um futuro mais brilhante e saudável para o Reino. Por meio do seu compromisso com iniciativas pioneiras de saúde digital, programas educacionais abrangentes e novos empreendimentos de pesquisa, o hospital está remodelando a paisagem local e estabelecendo novos padrões de eficiência e acessibilidade.

Em uma era definida pelos avanços tecnológicos e com o impulso do Reino em direção à digitalização, o KFSH&RC está na vanguarda da integração digital da saúde entre seus pares locais, alavancando serviços de telemedicina de ponta, consultas virtuais e ferramentas orientadas por IA, como o ANFAL AI System, que transforma os resultados dos pacientes por meio de insights preditivos e atendimento personalizado, garantindo os melhores resultados para a satisfação do paciente.

As iniciativas de saúde digital do KFSH&RC se estendem ao tratamento de ameaças mais amplas à saúde por meio de tecnologias como Sequenciamento Genômico Completo (WGS) e Radioterapia Avançada. O hospital também foi pioneiro no transplante de órgãos, realizando o primeiro transplante de fígado totalmente robótico do mundo e introduzindo inovações na região, como a Harmony Transcatheter Pulmonary Valve (TPV), melhorando a recuperação e a experiência do paciente. Essas tecnologias facilitam planos de tratamento personalizados e melhoram a precisão e a velocidade dos diagnósticos médicos, contribuindo significativamente para a elevação dos padrões de atendimento ao paciente e uma infraestrutura de saúde sustentável e resiliente, alinhada com os objetivos do Programa de Transformação do Setor de Saúde.

O KFSH&RC continua a expandir os limites da pesquisa médica abordando desafios urgentes de saúde e contribuindo para o cenário de saúde pública da Arábia Saudita, com descobertas como o gene PfAP2-MRP, crucial para o tratamento da malária, e a identificação da nova cepa de bactérias Riyadhensis. Essas descobertas não apenas melhoraram a precisão diagnóstica, mas também facilitaram intervenções precoces, garantindo suporte oportuno e eficaz ao paciente, de acordo com os objetivos nacionais de redução da prevalência de doenças crônicas.

Esses esforços abrangentes são apoiados pelas robustas iniciativas educacionais do KFSH&RC, que preparam a próxima geração de profissionais médicos por meio de programas de treinamento e colaborações internacionais.

Reconhecido pela ‘Brand Finance’ em 2024 como a marca de saúde mais valiosa da Arábia Saudita e do Oriente Médio pelo segundo ano consecutivo, tendo ocupado o 9º lugar na Arábia Saudita e o 28º no Oriente Médio. Além disso, o KFSH&RC se destaca como o único hospital do mundo a ser classificado entre as dez marcas mais valiosas do país.

Sobre o King Faisal Specialist Hospital & Research Centre (KFSH&RC):

O King Faisal Specialist Hospital & Research Centre (KFSH&RC) é uma instituição de saúde líder no Oriente Médio, idealizada para ser a escolha ideal para todos os pacientes que procuram cuidados de saúde especializados. O hospital tem uma longa história de tratamento de câncer, doença cardiovascular, transplante de órgãos, neurociências e genética.

Em 2024, o “Brand Finance” classificou o King Faisal Specialist Hospital & Research Centre como o melhor centro médico acadêmico do Oriente Médio e da África e entre os 20 melhores do mundo pelo segundo ano consecutivo. Além disso, em 2024 ele foi reconhecido como um dos principais provedores de cuidado de saúde pela revista Newsweek.

Como parte da Saudi Vision 2030, um decreto real foi emitido em 21 de dezembro de 2021 visando transformar o hospital em uma entidade independente, sem fins lucrativos e de propriedade do governo, abrindo caminho para um programa abrangente de transformação com objetivo de alcançar a liderança global em cuidados de saúde por meio da excelência e inovação.

INFORMAÇÃO DE CONTATO:

Para mais informações, contate:

Sr. Essam Al-Zahrani, Dirigente Interino de Assuntos de Mídia, 0555254429

Sr. Abdullah Al-Awn, Editor Sênior de Mídia, 0556294232

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/003e76ab-3d93-42d4-9edf-5e652a14c559

GlobeNewswire Distribution ID 9115602

Posted on

KFSH&RC Pushes Boundaries with a Year of Achievements Across Three Centres of Excellence

KFSH&RC Pushes Boundaries with a Year of Achievements Across Three Centres of Excellence

RIYADH, Saudi Arabia, May 10, 2024 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSH&RC) has experienced a year of achievements across its three Centres of Excellence—Oncology, Genomics, and Transplantation.

KFSH&RC’s Oncology Centre of Excellence continues to lead the fight against the disease in the Kingdom. This year alone, the centre has treated 25% of all cancer cases in Saudi Arabia, achieving a 50% overall recovery rate and up to 90% recovery in leukemia cases. With almost five decades of service, the centre’s commitment to providing advanced cancer treatments is evident in its adoption of technologies such as CAR T-cell therapy and liquid biopsy, which provide less invasive alternatives to traditional methods, along with extensive bone marrow transplants, and revolutionary techniques like Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

KFSH&RC Pushes Boundaries with a Year of Achievements Across Three Centres of Excellence

Notably, KFSH&RC has achieved a milestone by completing over 100 CAR T-cell therapy procedures, a novel treatment that genetically modifies a patient’s immune cells to fight cancer. This achievement puts it on par with renowned institutions that are also advancing CAR-T cell therapy for various blood cancers and exploring expanded applications through clinical trials and new treatment protocols. Furthermore, the centre’s focus on pediatric oncology boasts a 97% five-year survival rate for renal tumors and a 92% survival rate for acute lymphoblastic leukemia in children.

With rapid advancements in genomic medicine, KFSH&RC is adopting next-generation sequencing technologies into patient care in its Genomic Centre, revolutionizing local and regional approaches to disease management. KFSH&RC’s discovery of the bacterial strain Stenotrophomonas Riyadhensis, facilitated by whole-genome sequencing (WGS) technology, has contributed to our understanding of bacterial antibiotic resistance mechanisms. With 15,698 patient visits and over 5,658 whole genomes completed in 2023, the centre ensures that prevention, diagnosis, and treatment are precise and personalized.

KFSH&RC’s Organ Transplant Centre of Excellence (OTCoE) continues to be the primary contributor to organ transplantation activities in the Kingdom, accounting for 65% of all transplants performed nationally. In 2023, OTCoE performed 1,092 solid organ transplants, including the world’s first fully robotic liver transplant— where doctors employed robotic technology to conduct surgery on both patient and donor — an achievement that places the centre at the forefront of global transplantation practices.

As KFSH&RC continues to push the boundaries of what is possible in medical science, its efforts not only inspire but also significantly impact the global healthcare community, reaffirming its role as a leader in medical innovation and specialized healthcare.

About King Faisal Specialist Hospital & Research Centre (KFSH&RC):

King Faisal Specialist Hospital & Research Centre (KFSH&RC) stands as a leading healthcare institution in the Middle East, envisioned to be the optimal choice for every patient seeking specialized healthcare. The hospital boasts a rich history in the treatment of cancers, cardiovascular diseases, organ transplantation, neurosciences, and genetics.

In 2024, “Brand Finance” ranked King Faisal Specialist Hospital & Research Centre as the top academic medical centre in the Middle East and Africa, and among the top 20 globally for the second consecutive year. Additionally, in 2024, it was recognized as one of the leading global healthcare providers by Newsweek magazine.

As part of Saudi Vision 2030, a royal decree was issued on December 21, 2021, to transform the hospital into an independent, non-profit, government-owned entity, paving the way for a comprehensive transformation program aimed at achieving global leadership in healthcare through excellence and innovation.

CONTACT INFORMATION

For more information, please contact:

Mr. Essam Al-Zahrani, Acting Media Affairs Head, 0555254429

Mr. Abdullah Al-Aown, Media Coordination Officer, 0556294232

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e99afd2f-d5c6-400e-9290-26b36a580bee

GlobeNewswire Distribution ID 9115490

Posted on

Curia e Carterra Fazem Parceria em Simpósio para o Avanço da Pesquisa Biotecnológica do Noroeste do Pacífico

ALBANY, N.Y. e SALT LAKE CITY, May 10, 2024 (GLOBE NEWSWIRE) — A Curia, uma organização líder em contratos de pesquisa, desenvolvimento e fabricação, e a Carterra Inc., líder mundial em descoberta de medicamentos de moléculas pequenas e anticorpos de alto rendimento sem rótulos, anunciaram hoje sua parceria para a realização de um simpósio de produtos biológicos de alto rendimento previsto para 31 de maio no Residence Inn do Marriott em Seattle, Washington.

O objetivo da colaboração é promover o crescente foco em biotecnologia na região Noroeste do Pacífico dos EUA e Canadá. O simpósio reunirá todos os níveis de liderança científica das comunidades de biotecnologia e farmacêutica.

“Estamos muito entusiasmados com a parceria com a Carterra para organizar este simpósio de descoberta de anticorpos, reunindo a comunidade de biotecnologia do Noroeste do Pacífico e compartilhando os mais recentes avanços na descoberta de anticorpos”, disse Steve Lavezoli, Vice-Presidente de Produtos Biológicos da Curia. “Também estamos prontos para compartilhar nossos fluxos de trabalho de descoberta ideal de anticorpos de alta qualidade e acelerados para a primeira descoberta, desenvolvimento e fabricação clínica de anticorpos humanos. Os anticorpos descobertos e/ou projetados com a tecnologia de plataforma da Curia são para a área de clínica e temos mais de 230 campanhas bem-sucedidas de descoberta de anticorpos realizadas para a comunidade de biotecnologia.”

A velocidade, a experiência científica e a eficiência podem superar as altas taxas de atrito da descoberta precoce de anticorpos e alcançar a primeira distribuição no mercado de novas terapêuticas. O simpósio destacará a plataforma tecnológica e os serviços integrados da Curia com foco no desenvolvimento de sistemas aprimorados de camundongos para geração de anticorpos e triagem de células B únicas de alto rendimento. A combinação de sequenciamento de próxima geração (NGS) e produção recombinante rápida de quantidades de miligrama para grama de anticorpo monoclonal purificado (mAb) acelera significativamente a identificação de condutores candidatos ao desenvolvimento.

Desde 2017, a Carterra tem vendido seu potente biossensor de alto rendimento LSA® para analisar e caracterizar anticorpos com Ressonância Plasmônica de Superfície (SPR). Com o lançamento da sua plataforma LSAXT no ano passado, a Carterra passou a oferecer produtos que podem realizar análises de moléculas pequenas, bem como a descoberta de anticorpos. A plataforma LSA foi destaque em vários artigos revisados por pares em Science, Nature e Cell, detalhando o caminho de várias terapêuticas que estão entrando em ensaios clínicos. No simpósio, vários cientistas líderes em biofarmacêutica compartilharão suas ideias sobre suas áreas específicas de descoberta de medicamentos e destacarão o impacto transformador da integração da tecnologia HT-SPR, IA/ML e outras novas tecnologias.

“Estamos entusiasmados com a nossa parceria com a Curia no nosso simpósio. Os simpósios Carterra são eventos científicos que organizamos todos os anos nos EUA e na Europa”, disse Chris M. Silva, Vice-Presidente de Marketing e Produtos da Carterra. “Esses simpósios nos ajudam a compartilhar os mais recentes avanços tecnológicos e dados importantes gerados a partir dos fluxos de trabalho de cientistas que usam as plataformas sem rótulos da Carterra. A nossa entrada no noroeste do Pacífico é uma oportunidade para aumentar o entendimento mais profundo da tecnologia para produtos farmacêuticos e biotecnológicos nesta região.”

Clique aqui para confirmar presença no evento. É necessário inscrição pois temos vagas limitadas.

Sobre a Curia:
A Curia é uma Organização de Desenvolvimento e Fabricação de Contratos (CDMO) com mais de 30 anos de experiência, uma rede integrada de 27 locais globais e mais de 3.500 funcionários em parceria com clientes biofarmacêuticos para levar ao mercado terapias que mudam a vida. Nossas ofertas de produtos biológicos e pequenas moléculas abrangem a descoberta através da comercialização, com capacidades regulatórias e analíticas integradas. Nossos especialistas científicos e de processos, e instalações de última geração oferecem a melhor experiência em fabricação de medicamentos e produtos farmacêuticos. Da curiosidade à cura, proporcionamos todas as etapas para a melhoria da vida dos pacientes. Visite-nos em curiaglobal.com.

Sobre a Carterra, Inc.:
A Carterra, Inc. é uma empresa privada. Sua tecnologia HT-SPR fornece aos clientes de descoberta de medicamentos de moléculas grandes e pequenas, o rendimento e a funcionalidade de triagem e caracterização que são dimensionados com aplicativos de nível ômico, condensando meses de trabalho em dias. Nossas soluções viabilizaram múltiplas terapias e pesquisas inovadoras e ajudaram pesquisadores acadêmicos e translacionais e empresas biofarmacêuticas em oncologia, imunologia, neurociência e muito mais.  A Carterra está sediada em Salt Lake City, Utah, e tem Centros de Experiência do Cliente em São Francisco, Salt Lake City, Boston, Manchester, Inglaterra e Munique, Alemanha. Os produtos Carterra estão disponíveis na Ásia-Pacífico e na Oceania através do nosso distribuidor exclusivo, Revvity. Para mais informação, visite www.carterra-bio.com ou conecte-se conosco no LinkedIn ou X (Twitter).

Contato da Curia:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Contato para Mídia da Carterra:
Cheri Salazar
(408) 594-9400
csalazar@carterra-bio.com

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/020a0a28-86f0-4f6c-96f2-0eaa01c82784

GlobeNewswire Distribution ID 9115418

Posted on

Curia et Carterra coorganisent un symposium sur les produits biologiques pour encourager la recherche en biotechnologie dans le nord-ouest du Pacifique

ALBANY, New York et SALT LAKE CITY, 10 mai 2024 (GLOBE NEWSWIRE) — Curia, une organisation de premier plan du domaine de la recherche, du développement et de la fabrication sous contrat, et Carterra Inc., leader mondial de la découverte d’anticorps et de médicaments à petites molécules sans étiquette à haut débit, annoncent ce jour un partenariat ciblé sur l’organisation d’un symposium sur les produits biologiques à haut débit, prévu le 31 mai au Residence Inn at Marriott de Seattle, dans l’État de Washington.

L’objectif de cette collaboration vise la promotion de l’intérêt croissant suscité par la biotechnologie dans la zone nord-ouest du Pacifique des États-Unis et du Canada. Le symposium réunira des professionnels de tous niveaux de direction scientifique de la biotechnologie et de la pharmaceutique.

« Nous sommes ravis de nous associer à Carterra pour organiser ce symposium axé sur la découverte d’anticorps, qui réunira l’ensemble de la communauté biotechnologique du nord-ouest du Pacifique et permettra de partager les dernières avancées en matière de découverte d’anticorps », observe Steve Lavezoli, vice-président des produits biologiques chez Curia. Et de poursuivre : « Nous sommes également impatients d’échanger sur nos meilleurs flux de travail, de haute qualité et accélérés pour la découverte, le développement et la fabrication clinique d’anticorps en vue d’une première administration chez l’être humain. Les anticorps découverts et/ou conçus à l’aide de la plateforme technologique de Curia sont utilisés en clinique et nous avons mené avec succès plus de 230 campagnes de découverte d’anticorps au bénéfice de la communauté biotechnologique. »

La rapidité, l’expertise scientifique et l’efficacité permettent de surmonter les forts taux de rotation de la découverte précoce d’anticorps et d’assurer la mise en marché de nouveaux produits thérapeutiques. Le symposium mettra en lumière la plateforme technologique et les services intégrés de Curia, en exerçant un focus sur le développement de modèles murins améliorés pour la génération d’anticorps et le criblage de cellules B uniques à haut débit. La combinaison du séquençage de nouvelle génération (SNG) et de la production recombinante rapide de quantités d’anticorps monoclonaux (AcM) purifiés (de milligramme en gramme) accélère considérablement l’identification des approches de développement de produits candidats.

Depuis 2017, Carterra commercialise son puissant biocapteur à haut débit LSA®, conçu pour l’analyse et la caractérisation des anticorps à l’aide de la résonance plasmonique de surface (ou SPR pour Surface Plasmon Resonance). Depuis le lancement de sa plateforme LSAXT l’année dernière, Carterra propose des produits en mesure d’effectuer l’analyse de petites molécules et permettre la découverte d’anticorps. La plateforme LSA a fait l’objet de plusieurs articles évalués par des pairs dans Science, Nature et Cell, détaillant le parcours de plusieurs produits thérapeutiques faisant leur entrée dans les essais cliniques. Lors du symposium, plusieurs scientifiques renommés du secteur biopharmaceutique partageront les éclairages propres à leurs domaines spécifiques de découverte de médicaments et mettront en évidence l’effet novateur de l’intégration de la technologie HT-SPR, de l’intelligence artificielle et de l’apprentissage automatique et d’autres nouvelles technologies.

« Nous sommes enchantés de nous associer à Curia pour organiser ce symposium. Les symposiums de Carterra sont des événements scientifiques que nous organisons chaque année aux États-Unis et en Europe », précise Chris M. Silva, vice-président du marketing et des produits chez Carterra, avant d’ajouter : « Ils nous permettent de partager les dernières avancées technologiques et les données significatives générées par les flux de travail des scientifiques utilisant les plateformes sans étiquette de Carterra. Nous rendre dans le nord-ouest du Pacifique nous permettra d’induire une meilleure compréhension de la technologie applicable aux domaines pharmaceutique et biotechnologique dans cette région. »

Cliquez ici pour vous inscrire à l’événement. L’inscription est obligatoire car le nombre de places est limité.

À propos de Curia :
Curia est une organisation de développement et de fabrication sous contrat (ou CDMO pour Contract Development and Manufacturing Organization) avec plus de 30 ans d’expérience à son actif, qui exploite un réseau intégré de 27 sites à travers le monde et emploie plus de 3 500 collaborateurs travaillant en partenariat avec des clients biopharmaceutiques pour commercialiser des traitements ayant un véritable impact sur la vie des personnes. Nos offres de produits biologiques et de petites molécules vont de la découverte à la commercialisation, et intègrent des capacités réglementaires et analytiques intégrées. Nos scientifiques, nos experts en processus et nos installations de pointe apportent une expérience de premier ordre dans la fabrication de substances et de produits pharmaceutiques. De la curiosité au traitement, nous réalisons toutes les étapes pour améliorer la vie des patients. Consultez notre site à l’adresse suivante : www.curiaglobal.com.

À propos de Carterra, Inc. :
Carterra, Inc. est une société privée. Sa technologie HT-SPR délivre aux clients du secteur de la découverte de médicaments à petites et grandes molécules un débit de criblage et de caractérisation et des fonctionnalités qui s’adaptent aux applications de niveau omique, ramenant ainsi des mois de travail à quelques jours à peine. Nos solutions ont permis la mise au point de nombreux traitements et de recherches révolutionnaires. Elles ont appuyé les chercheurs universitaires et translationnels ainsi que les sociétés biopharmaceutiques spécialisés dans les domaines de l’oncologie, de l’immunologie, des neurosciences, entre autres. Carterra est domiciliée à Salt Lake City, dans l’Utah, et exploite des centres d’expérience client situés à San Francisco, Salt Lake City et Boston, ainsi qu’à Manchester, en Angleterre, et à Munich, en Allemagne. Les produits Carterra sont disponibles en Asie-Pacifique et en Océanie par l’intermédiaire de notre distributeur exclusif, Revvity. Pour en savoir plus, consultez le site www.carterra-bio.com ou retrouvez-nous sur LinkedIn ou X (Twitter).

Coordonnées Curia :
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Interlocutrice auprès des médias :
Cheri Salazar
(408) 594-9400
csalazar@carterra-bio.com

Une photo accompagnant ce communiqué est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/020a0a28-86f0-4f6c-96f2-0eaa01c82784

GlobeNewswire Distribution ID 9115418

Posted on

King Faisal Specialist Hospital & Research Centre Leading Health Sector Transformation in Saudi Arabia

King Faisal Specialist Hospital & Research Centre Leading Health Sector Transformation in Saudi Arabia

RIYADH, Saudi Arabia, May 09, 2024 (GLOBE NEWSWIRE) — Harvard University — Eight years into Vision 2030, Saudi Arabia has made significant strides with digital innovations and enhanced access to quality care. Strategic investments in infrastructure, technology, and talent, have led to advancements revolutionizing patient care delivery and elevating the standards of healthcare locally. These efforts have notably raised the average life expectancy, reduced mortality rates, and enhanced overall well-being across the Kingdom.

Central to these achievements, King Faisal Specialist Hospital & Research Centre (KFSH&RC), renowned for its specialized care and treatments across critical fields such as oncology, cardiology, organ transplantation, and genetics has positioned itself as a leader in specialized patient care, taking the charge towards a brighter, healthier future for the Kingdom. Through its commitment to pioneering digital health initiatives, comprehensive educational programs, and novel research endeavors, it is reshaping the local landscape, and setting new standards of efficiency and accessibility.

In an era defined by technological advancements, and with the Kingdom’s push towards digitalization, KFSH&RC stands at the forefront of digital health integration among its local peers, leveraging cutting-edge telemedicine services, virtual consultations, and AI-driven tools such as the ANFAL AI System that transforms patient outcomes through predictive insights and personalized care, ensuring the best outcomes for patient satisfaction.

KFSH&RC’s digital health initiatives extend to addressing broader health threats through technologies such as Whole Genomic Sequencing (WGS) and Advanced Radiation Therapy. The hospital has also pioneered organ transplantation by performing the world’s first fully robotic liver transplant and introduced to the region innovations like the Harmony Transcatheter Pulmonary Valve (TPV), enhancing patient recovery and experience. These technologies facilitate personalized treatment plans and improve the accuracy and speed of medical diagnostics, contributing significantly to the elevation of patient care standards and a sustainable, resilient healthcare infrastructure in line with the objectives of the Health Sector Transformation Program.

KFSH&RC continues to push the boundaries of medical research addressing pressing health challenges and contributing to Saudi Arabia’s public health landscape, with discoveries like the PfAP2-MRP gene crucial for malaria treatment and the identification of the new Riyadhensis bacteria strain. These discoveries have not only improved diagnostic accuracy but also facilitated early interventions, ensuring timely and effective patient support, in line with the national objectives to reduce chronic disease prevalence.

These comprehensive efforts are supported by KFSH&RC’s robust educational initiatives, which prepare the next generation of medical professionals through training programs and international collaborations.

Recognized by ‘Brand Finance’ in 2024 as the most valuable healthcare brand in Saudi Arabia and the Middle East for the second consecutive year, placing 9th in Saudi Arabia and 28th in the Middle East. Additionally, KFSH&RC stands out as the only hospital worldwide to be ranked among its country’s top ten most valuable brands.

About King Faisal Specialist Hospital & Research Centre (KFSH&RC):

King Faisal Specialist Hospital & Research Centre (KFSH&RC) stands as a leading healthcare institution in the Middle East, envisioned to be the optimal choice for every patient seeking specialized healthcare. The hospital boasts a rich history in the treatment of cancers, cardiovascular diseases, organ transplantation, neurosciences, and genetics.

In 2024, “Brand Finance” ranked King Faisal Specialist Hospital & Research Centre as the top academic medical centre in the Middle East and Africa, and among the top 20 globally for the second consecutive year. Additionally, in 2024, it was recognized as one of the leading global healthcare providers by Newsweek magazine.

As part of Saudi Vision 2030, a royal decree was issued on December 21, 2021, to transform the hospital into an independent, non-profit, government-owned entity, paving the way for a comprehensive transformation program aimed at achieving global leadership in healthcare through excellence and innovation.

CONTACT INFORMATION

For more information, please contact:

Mr. Essam Al-Zahrani, Media Affairs Head, 0555254429

Mr. Abdullah Al-Aown, Media Coordination Officer, 0556294232

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/003e76ab-3d93-42d4-9edf-5e652a14c559

Copyright © 2024 GlobeNewswire, Inc.

GlobeNewswire Distribution ID 9114722

Posted on

Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific Northwest

Curia & Carterra Biologics Symposium

Biologics symposium slated for May 31 in Seattle, WA

ALBANY, N.Y. and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization and Carterra Inc., the world leader in label-free high throughput antibody and small molecule drug discovery, today announced their partnership in hosting a high-throughput biologics symposium slated for May 31 at the Residence Inn at Marriott in Seattle, Washington.

The purpose of the collaboration is to promote the rising biotech focus within the Pacific Northwest region of the U.S and Canada. The symposium will bring together all levels of scientific leadership from the biotech and pharma communities.

“We are thrilled to be partnering with Carterra to organize this antibody discovery symposium, bringing the Pacific Northwest biotech community together and sharing the latest advances in antibody discovery,” said Steve Lavezoli, Vice President of Biologics at Curia. “We are also looking forward to sharing our optimal, high-quality and accelerated antibody discovery workflows to first-to-human antibody discovery, development and clinical manufacturing. Antibodies discovered and/or engineered with Curia’s platform technology are in the clinic and we have over 230 successful antibody discovery campaigns performed for the biotech community.”

Speed, scientific expertise and efficiency can surmount the high attrition rates of early antibody discovery and achieve first-to-market delivery of new therapeutics. The symposium will highlight Curia’s technology platform and integrated services with a focus on the development of enhanced mouse systems for antibody generation and high-throughput single B cell screening. The combination of next generation sequencing (NGS) and rapid recombinant production of milligram to gram quantities of purified monoclonal antibody (mAb) significantly accelerates identification of development candidate leads.

Since 2017, Carterra has been selling its powerful LSA® high-throughput biosensor to analyze and characterize antibodies using Surface Plasmon Resonance (SPR). With the launch of its LSAXT platform last year, Carterra now offers products that can perform small molecule analysis as well as antibody discovery. The LSA platform has been profiled in several peer-reviewed papers in Science, Nature and Cell, detailing the path of multiple therapeutics entering clinical trials. At the symposium, several leading scientists in biopharma will be sharing their insights into their specific areas of drug discovery and will highlight the transformative impact of integrating HT-SPR technology, AI/ML and other new technologies.

“We are excited to be partnering with Curia on our symposium. Carterra symposia are scientific events that we host each year throughout the U.S. and Europe,” stated Chris M. Silva, Vice President of Marketing and Product at Carterra. “These symposia help us to share the latest technology advancements and important data generated from the workflows of scientists using Carterra’s label-free platforms. Coming to the Pacific Northwest is an opportunity to create a deeper understanding of the technology in pharma and biotechs in this region.”

Click here to RSVP for the event. Registration is required as seating is limited.

About Curia:
Curia is a Contract Development and Manufacturing Organization (CDMO) with over 30 years of experience, an integrated network of 27 global sites and over 3,500 employees partnering with Biopharmaceutical customers to bring life-changing therapies to market. Our biologics and small molecules offerings span discovery through commercialization, with integrated regulatory and analytical capabilities. Our scientific and process experts and state-of-the-art facilities deliver best-in-class experience across drug substance and drug product manufacturing. From curiosity to cure, we deliver every step to improve patients’ lives. Visit us at curiaglobal.com.

About Carterra, Inc.:
Carterra, Inc. is a privately held company. Its HT-SPR technology provides large-molecule and small-molecule drug discovery customers with screening and characterization throughput and functionality that scales with omics-level applications, condensing months of work down to days. Our solutions have enabled multiple therapeutics and breakthrough research and helped academic and translational researchers and biopharmaceutical companies in oncology, immunology, neuroscience, and more.  Carterra is based in Salt Lake City, Utah, and has Customer Experience Centers in San Francisco, Salt Lake City, Boston, Manchester, England, and Munich, Germany. Carterra products are available in Asia-Pacific and Oceania through our exclusive distributor, Revvity. To learn more, visit www.carterra-bio.com or connect with us on LinkedIn or X (Twitter).

Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

Carterra Media Contact:
Cheri Salazar
(408) 594-9400
csalazar@carterra-bio.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/020a0a28-86f0-4f6c-96f2-0eaa01c82784

GlobeNewswire Distribution ID 9114095

Posted on

Hitachi Energy supports long-term operation of largest HVDC-connected wind energy project in U.S.

Multi-year agreement provides service solutions to the SunZia Transmission Project, linking New Mexico’s wind farms to Arizona’s grid, increasing renewable energy to Western States

Zurich, Switzerland, May 07, 2024 (GLOBE NEWSWIRE) — Hitachi Energy announced that it has signed a multi-year agreement with Pattern Energy to support its high-voltage direct current (HVDC) technologies for the SunZia Transmission Project. The link will connect the 3,515-megawatt (MW) SunZia Wind project in New Mexico to Arizona and Western states, which will be one of the world’s largest transmission links delivering renewable energy.

The long-term agreement will provide service solutions for the SunZia Transmission HVDC link, currently under construction1, owned by Pattern Energy, one of the world’s largest privately-owned developers and operators of renewable energy and transmission projects. Hitachi Energy’s HVDC Light® technology will efficiently transfer and integrate huge volumes of wind power over more than 885 kilometers (550 miles) into the regional power grid. This will significantly increase the availability of sustainable energy for homes and businesses throughout the region when it enters operation, which is expected in 2025.

EnCompass™ is Hitachi Energy’s portfolio of partnership-oriented service offerings, signaling a step-change in life cycle thinking. This order underlines Hitachi Energy’s commitment to trusted long-term partnerships and builds on its proven track record of delivering innovative and reliable energy service solutions 2.

When complete, SunZia Wind will have a total power capacity of 3,515 MW, enough clean, renewable electricity to provide power to approximately three million Americans3. The HVDC link will efficiently transmit up to 3,000 MW of this power west to Arizona. The HVDC Light system will be the largest voltage source converter (VSC) installation in the United States, one of the largest worldwide, and one of the country’s longest HVDC connections.

“We’re proud to be selected once again to provide our unique service expertise to keep the important SunZia link operating at maximum efficiency, performance, and reliability,” said Andreas Berthou, global head of the HVDC business at Hitachi Energy. “With our service solutions, we are building a partnership ecosystem to ensure continued support to the HVDC link throughout its lifetime, delivering cutting edge digital service with sustainability and customer-value at its core.”

“The SunZia transmission and Wind projects provide a roadmap to accelerate the transition to renewable energy,” said Paul Haberlein, VP of Operational Excellence at Pattern Energy. “SunZia will play a vital role in delivering clean and sustainable energy to Western states. Pattern selected Hitachi Energy, a global technology leader, as our partner to engineer, manufacture and maintain the HVDC converter stations after they enter operation.”

Service for an HVDC system includes a wide range of activities and support, including scheduled maintenance, cyber services, on-site engineering support and life cycle assessment of the HVDC Light stations.

Hitachi Energy recognizes that the energy transition begins with existing infrastructure and the company is championing the urgency and the pace of change needed to reach Net Zero.  Leveraging on the company’s century of experience and expertise, its dedicated teams deliver exceptional service solutions that cover the entire life cycle of their customer’s assets, ensuring resilient operations. The company offers expert advice at every stage of the process across the whole portfolio, addressing both present and future needs to help customers achieve a sustainable energy future.

Hitachi Energy pioneered commercial HVDC technology 70 years ago and has delivered more than half of the world’s HVDC projects and has the largest installed base of HVDC in the world.

Notes to editors

1 https://www.hitachienergy.com/se/sv/about-us/customer-success-stories/sunzia
2 https://www.hitachienergy.com/services-and-consulting/services/encompass-agreements
3 https://sunzia.net/impact/

About Hitachi Energy 
Hitachi Energy is a global technology leader that is advancing a sustainable energy future for all. We are advancing the world’s energy system to be more sustainable, flexible and secure and we collaborate with customers and partners to enable a sustainable energy future – for today’s generations and those to come. Hitachi Energy has a proven track record and unparalleled installed base in more than 140 countries, serving customers in utility, industry, transportation, data centers and infrastructure sectors. With innovative technologies and services including the integration of more than 150 gigawatts of HVDC links into the power system, we help make the energy value chain more efficient, making electricity more accessible to all. Together with stakeholders across sectors and geographies, we enable the digital transformation required to accelerate the energy transition towards a carbon-neutral future. Headquartered in Switzerland, we employ around 45,000 people in 90 countries and generate business volumes of around $13 billion USD.

https://www.hitachienergy.com
https://www.linkedin.com/company/hitachienergy
https://twitter.com/HitachiEnergy

About Hitachi, Ltd.
Hitachi drives Social Innovation Business, creating a sustainable society through the use of data and technology. We solve customers’ and society’s challenges with Lumada solutions leveraging IT, OT (Operational Technology) and products. Hitachi operates under the 3 business sectors of “Digital Systems & Services” – supporting our customers’ digital transformation; “Green Energy & Mobility” – contributing to a decarbonized society through energy and railway systems, and “Connective Industries” – connecting products through digital technology to provide solutions in various industries. Driven by Digital, Green, and Innovation, we aim for growth through co-creation with our customers. The company’s revenues as 3 sectors for fiscal year 2023 (ended March 31, 2024) totaled 8,564.3 billion yen, with 573 consolidated subsidiaries and approximately 270,000 employees worldwide. For more information on Hitachi, please visit the company’s website at https://www.hitachi.com.

Attachment

Kurt Steinert
Hitachi Energy North America
rebecca.bleasdale@hitachienergy.com

Global Media Relations
Hitachi Energy
media.relations@hitachienergy.com

GlobeNewswire Distribution ID 9112623

Posted on

Anaqua Unveils PATTSY WAVE Version 8 IP Management Software

New release empowers IP professionals with enhanced operational efficiency and functionality

BOSTON, May 07, 2024 (GLOBE NEWSWIRE) — Anaqua, the leading provider of innovation and intellectual property (IP) management technology, today announces the launch of PATTSY WAVE Version 8, the latest release of the patent and trademark management software. With this announcement, PATTSY WAVE Version 8 offers a streamlined IP management experience for IP professionals in corporations and law firms focused on efficient task execution.

Created to simplify workflows, mitigate risk, and elevate accuracy, Version 8’s new components help IP professionals manage their portfolios with greater precision and ease. New capabilities include:

  • Inventor Portal: A cutting-edge tool that enhances collaboration between inventors and legal teams. The Inventor Portal streamlines the invention disclosure process with customizable, no-code questionnaires, intuitive tracking mechanisms for inventor awards, and automated workflows for legal processing.
  • APIs: PATTSY WAVE’s APIs will provide a standard, reliable mechanism to share data with external applications. Clients will be able to retrieve bibliographic and action data from any of PATTSY WAVE’s primary modules.
  • Unlimited Parties & Customizable Roles: Users can now assign an unlimited number of responsible parties to any matter. Teams can also define roles applicable to their organization and create specialized roles associated with Action Categories.

PATTSY WAVE Version 8 also includes enhanced user experience and functionality with expanded data validation to provide global coverage and detailed assignment history, ensuring a comprehensive and intuitive system for all.

“With the release of PATTSY WAVE Version 8, Anaqua continues our commitment to empowering intellectual property professionals with innovative solutions that enhance efficiency, reduce risk, and drive productivity,” said Bob Romeo, CEO at Anaqua. “Version 8 is the ideal solution for IP professionals seeking a modern, integrated tool to drive their IP operations with speed, accuracy and control.”

For more information about PATTSY WAVE Version 8 and its latest features, visit anaqua.com/pattsy-wave/.

About Anaqua

Anaqua, Inc. is a premier provider of integrated intellectual property (IP) management technology solutions and services for corporations and law firms. Its IP management software solutions, AQX® and PATTSY WAVE®, both offer best practice workflows with big data analytics and tech-enabled services to create an intelligent environment designed to inform IP strategy, enable IP decision-making, and streamline IP operations, tailored to each segment’s need. Today, nearly half of the top 100 U.S. patent filers and global brands, as well as a growing number of law firms worldwide use Anaqua’s solutions. Over one million IP executives, attorneys, paralegals, administrators, and innovators use the platform for their IP management needs. The company’s global operations are headquartered in Boston, with offices across the U.S., Europe, Asia, and Australia. For additional information, please visit anaqua.com, or on Anaqua’s LinkedIn.

Company Contact:
Amanda Glagolev
Director, Communications
Anaqua
617-375-5808
aglagolev@anaqua.com

GlobeNewswire Distribution ID 9112617

Proudly powered by WordPress